In the prospective study, we enrolled travelers who visited the travel clinic between January 2017 and December 2019 for malaria chemoprophylaxis. According to CDC recommendations, travelers could choose one from mefloquine, atovaquone-proguanil, doxycycline, chloroquine, primaquine, and tafenoquine for primary malaria prophylaxis [23 ]. In Taiwan, we have mefloquine, a once weekly regimen, and 2 kinds of a once daily regimen to choose from: doxycycline and atovaquone-proguanil. We interviewed 173 travelers, of whom 7 on atovaquone-proguanil were excluded because of the small sample size, and 5 were excluded because they were lost to follow-up after their trip.
All enrolled 161 travelers were Taiwanese, and we communicated verbally in Chinese; the questionnaire was also written in Chinese. Informed consent was obtained from every participant in the study during the first clinic visit. This study was approved by Kaohsiung Medical University Hospital Institution Review Board, KMUH-IRB-970496.
All enrolled 161 travelers were Taiwanese, and we communicated verbally in Chinese; the questionnaire was also written in Chinese. Informed consent was obtained from every participant in the study during the first clinic visit. This study was approved by Kaohsiung Medical University Hospital Institution Review Board, KMUH-IRB-970496.
Free full text: Click here
